BRPI0509475A - matrizes de hidrogel aniÈnico com liberação modificada dependente do ph como veìculos de fármacos - Google Patents

matrizes de hidrogel aniÈnico com liberação modificada dependente do ph como veìculos de fármacos

Info

Publication number
BRPI0509475A
BRPI0509475A BRPI0509475-5A BRPI0509475A BRPI0509475A BR PI0509475 A BRPI0509475 A BR PI0509475A BR PI0509475 A BRPI0509475 A BR PI0509475A BR PI0509475 A BRPI0509475 A BR PI0509475A
Authority
BR
Brazil
Prior art keywords
modified release
drug carriers
hydrogel matrices
anionic hydrogel
dependent modified
Prior art date
Application number
BRPI0509475-5A
Other languages
English (en)
Inventor
Gaetano Giammona
Delia Mandracchia
Original Assignee
Sigma Tau Ind Famaceutiche Riu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Famaceutiche Riu filed Critical Sigma Tau Ind Famaceutiche Riu
Publication of BRPI0509475A publication Critical patent/BRPI0509475A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

MATRIZES DE HIDROGEL ANIÈNICO COM LIBERAçãO MODIFICADA DEPENDENTE DO PH COMO VEìCULOS DE FáRMACOS. A presente invenção refere-se a composições com liberação modificada dependente do pH que são descritas, consistindo em matrizes de hidrogel contendo um ou mais ingredientes ativos, nas quais as matrizes referidas são adequadas para liberar os ingredientes ativos referidos em uma maneira prolongada em dados sítios do como.
BRPI0509475-5A 2004-04-01 2005-02-16 matrizes de hidrogel aniÈnico com liberação modificada dependente do ph como veìculos de fármacos BRPI0509475A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000168A ITRM20040168A1 (it) 2004-04-01 2004-04-01 Composizione a rilascio modificato ph dipendente.
PCT/IT2005/000081 WO2005094792A1 (en) 2004-04-01 2005-02-16 Anionic hydrogel matrices with ph dependent modified release as drug carriers

Publications (1)

Publication Number Publication Date
BRPI0509475A true BRPI0509475A (pt) 2007-09-11

Family

ID=34961555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509475-5A BRPI0509475A (pt) 2004-04-01 2005-02-16 matrizes de hidrogel aniÈnico com liberação modificada dependente do ph como veìculos de fármacos

Country Status (20)

Country Link
US (1) US20070166383A1 (pt)
EP (1) EP1729732B1 (pt)
JP (1) JP2007530666A (pt)
KR (1) KR20060133578A (pt)
CN (1) CN1913875B (pt)
AT (1) ATE428405T1 (pt)
AU (1) AU2005228716B2 (pt)
BR (1) BRPI0509475A (pt)
CA (1) CA2551797A1 (pt)
CY (1) CY1109209T1 (pt)
DE (1) DE602005013935D1 (pt)
DK (1) DK1729732T3 (pt)
ES (1) ES2325626T3 (pt)
HR (1) HRP20090329T1 (pt)
IT (1) ITRM20040168A1 (pt)
PL (1) PL1729732T3 (pt)
PT (1) PT1729732E (pt)
RS (1) RS51178B (pt)
SI (1) SI1729732T1 (pt)
WO (1) WO2005094792A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4746883B2 (ja) * 2005-01-28 2011-08-10 リンテック株式会社 ハイドロゲル基剤、パップ剤基剤、パップ剤及び水性ゲルシート
BRPI0918693A2 (pt) 2008-12-31 2016-07-26 3M Innovative Properties Co dispositivos para amostragem e métodos para concentração de microorganismos
EP2379226B1 (en) 2008-12-31 2016-04-20 3M Innovative Properties Company Live bioload detection using microparticles
JP5972174B2 (ja) 2009-12-30 2016-08-17 スリーエム イノベイティブ プロパティズ カンパニー 微小粒子を用いた生きた生物負荷の検出法
US8845801B2 (en) 2009-12-30 2014-09-30 Regents Of The University Of Minnesota Bone cement and method
KR101228106B1 (ko) * 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
WO2011090349A2 (ko) * 2010-01-21 2011-07-28 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
CN103330702B (zh) * 2013-07-02 2016-03-02 江苏长泰药业有限公司 含有拟交感神经胺盐和诱导凝胶体系的医药组合物
CN108452291A (zh) * 2018-07-04 2018-08-28 西南大学 用天然丝胶蛋白治疗溃疡性结肠炎的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071508A (en) * 1975-02-11 1978-01-31 Plastomedical Sciences, Inc. Anionic hydrogels based on hydroxyalkyl acrylates and methacrylates
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
DE19653631A1 (de) * 1996-12-20 1998-06-25 Basf Coatings Ag Verfahren zum Herstellen von durch Strahlung vernetzbaren polymeren Acryl- oder Methacrylsäureestern
ATE295189T1 (de) * 1997-06-03 2005-05-15 Innogenetics Nv Neue arzneimittel auf der basis von polymeren aus mit methacrylamid modifizierter gelatine
JP2002536317A (ja) * 1999-02-03 2002-10-29 パウダージェクト リサーチ リミテッド ヒドロゲル粒子処方物
US6547182B2 (en) * 2001-07-19 2003-04-15 Aerojet-General Corporation Solid rocket motor bolted thrust takeout structure
US7204997B2 (en) * 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto

Also Published As

Publication number Publication date
PL1729732T3 (pl) 2009-09-30
PT1729732E (pt) 2009-07-02
CY1109209T1 (el) 2014-07-02
DK1729732T3 (da) 2009-08-10
KR20060133578A (ko) 2006-12-26
US20070166383A1 (en) 2007-07-19
CN1913875A (zh) 2007-02-14
SI1729732T1 (sl) 2009-08-31
AU2005228716A1 (en) 2005-10-13
DE602005013935D1 (de) 2009-05-28
HRP20090329T1 (hr) 2009-09-30
EP1729732B1 (en) 2009-04-15
WO2005094792A1 (en) 2005-10-13
ATE428405T1 (de) 2009-05-15
CN1913875B (zh) 2011-08-31
JP2007530666A (ja) 2007-11-01
CA2551797A1 (en) 2005-10-13
RS51178B (sr) 2010-10-31
ITRM20040168A1 (it) 2004-07-01
ES2325626T3 (es) 2009-09-10
AU2005228716B2 (en) 2010-07-15
EP1729732A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
CY1109209T1 (el) Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
TR201911270T4 (tr) Polimerik mirsen bileşimleri.
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
UY30816A1 (es) Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
DK1799748T3 (da) Bionedbrydelige kationiske polymerer
BRPI0513310A (pt) análogos de tetrapeptìdeo
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
TW200800967A (en) Benzimidazole thiophene compounds
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
DOP2006000096A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
AR055615A1 (es) Dispersiones amorfas solidas
TW200613003A (en) Active compound-containing solid moulded bodies for external use against parasites on animals
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
ECSP066909A (es) Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
GT200600121A (es) Novedosos derivados de triazolopirimidina
MX2007013327A (es) Formulaciones de liberacion prolongada.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
BRPI0507664A (pt) compostos com atividade antitumor
TNSN07438A1 (en) Prolonged release formulation of active principles having a ph-dependent solubility
PA8627401A1 (es) Composiciones diuréticas de liberación prolongada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.